| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2023―Oct―12 |
Targeting Cyclophilin A and CD147 to Inhibit Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and SARS-CoV-2-Induced Inflammation |
Fan Yang, Chenglong Liu, Pengyuan Li, Aihua Wu, Yue Ma-Lauer, Hao Zhang, Zhuang Su, Wei Lu, Albrecht von Brunn, Di Zhu |
| 2 |
[GO] |
2022―Feb―01 |
A Comment on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” |
Eric K. Johnson |
| 3 |
[GO] |
2022―Feb―01 |
Response to Comments on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” |
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. Cherrington |
| 4 |
[GO] |
2021―Sep―09 |
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites |
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. CHERRINGTON |
| 5 |
[GO] |
2020―Oct―21 |
Dysregulation of ACE2 Expression and Function in Co-morbid Disease Conditions Possibly Contributes to COVID-19 Complication Severity |
Safaa Hammoud, Zena Wehbe, Samar Abdelhady, Firas Kobeissy, Ali Hussein Eid, Ahmed F El-Yazbi |
| 6 |
[GO] |
2020―Sep―10 |
Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection |
Omid Tavassoly, Farinaz Safavi, Iman Tavassoly |
|
